Browse

First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer

DC Field Value Language
dc.contributor.authorPark, Se Hoon-
dc.contributor.authorBang, Soo-Mee-
dc.contributor.authorCho, Eun Kyung-
dc.contributor.authorBaek, Jeong Heum-
dc.contributor.authorOh, Jae Hwan-
dc.contributor.authorIm, Seock Ah-
dc.contributor.authorPark, Young Suk-
dc.contributor.authorShin, Dong Bok-
dc.contributor.authorLee, Jae Hoon-
dc.date.accessioned2010-01-11T07:05:32Z-
dc.date.available2010-01-11T07:05:32Z-
dc.date.issued2004-08-28-
dc.identifier.citationOncology. 2004;66(5):353-7.en
dc.identifier.issn0030-2414 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15331921-
dc.identifier.urihttps://hdl.handle.net/10371/29353-
dc.description.abstractOBJECTIVE: The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma. METHODS: Patients with histologically proven advanced colorectal adenocarcinoma received a first-line chemotherapy with irinotecan 240 mg/m2 on day 1 and capecitabine 2,000 mg/m2/day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest. Treatment was repeated every 3 weeks. RESULTS: Thirty-nine patients were registered, and 36 were assessable for responses. Sixteen objective responses (44%) were observed with a median response duration of 6.9 months. Stable disease was documented in 14 cases (39%). The median time to progression was 6.7 months. The median overall survival was not reached at the time of analysis, and the 1-year survival rate was 67%. Two patients died: 1 due to sepsis not complicating myelosuppression, and 1 patient, known as a hepatitis B virus carrier prior to chemotherapy, died of hepatic failure, the cause of which was not clinically verified. Frequently encountered therapy-related events were leukopenia and gastrointestinal side effects including diarrhea. Severe hand-and-foot syndrome was observed in only 1 patient. CONCLUSIONS: The combination chemotherapy of irinotecan and capecitabine is an active and tolerable regimen for advanced colorectal adenocarcinoma, but the observed deaths suggest a future randomized trial that requires a cautious patient selection.en
dc.language.isoenen
dc.publisherKargeren
dc.subjectAdenocarcinoma/*drug therapyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCamptothecin/*administration & dosage/adverse effects/*analogs &en
dc.subjectderivativesen
dc.subjectColorectal Neoplasms/*drug therapyen
dc.subjectDeoxycytidine/*administration & dosage/adverse effects/*analogs &en
dc.subjectderivativesen
dc.subjectFemaleen
dc.subjectFluorouracil/analogs & derivativesen
dc.subjectHumansen
dc.subjectLeukopenia/chemically induceden
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectSurvival Rateen
dc.titleFirst-line chemotherapy with irinotecan plus capecitabine for advanced colorectal canceren
dc.typeArticleen
dc.contributor.AlternativeAuthor박세훈-
dc.contributor.AlternativeAuthor방수미-
dc.contributor.AlternativeAuthor조은경-
dc.contributor.AlternativeAuthor백정흠-
dc.contributor.AlternativeAuthor오재환-
dc.contributor.AlternativeAuthor임석아-
dc.contributor.AlternativeAuthor신동복-
dc.contributor.AlternativeAuthor이재훈-
dc.contributor.AlternativeAuthor박영석-
dc.identifier.doi10.1159/000079482-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse